Document is current
Any future updates will be listed below
-
Authors
Damato, Angela https://orcid.org/0000-0001-8286-1274
Esposito Abate, Riziero
Tessitore, Simona
Frezzetti, Daniela
Maiello, Monica Rosaria
Righelli, Dario https://orcid.org/0000-0003-1504-3583
Bergamo, Francesca
Antonuzzo, Lorenzo
Nasti, Guglielmo
Pietrantonio, Filippo
Tonini, Giuseppe
Latiano, Tiziana
Bordonaro, Roberto
Rosati, Gerardo
Giommoni, Elisa https://orcid.org/0000-0002-1715-8440
Iachetta, Francesco
Larocca, Mario
Maiello, Evaristo
Lonardi, Sara https://orcid.org/0000-0002-7593-8138
Romagnani, Alessandra https://orcid.org/0000-0002-6112-3667
Maglietta, Giuseppe
De Luca, Antonella
Normanno, Nicola https://orcid.org/0000-0002-7158-2605
Pinto, Carmine
- License Information
-
More Information
Article History
Received: 24 March 2025
Accepted: 26 February 2026
First Online: 25 March 2026
Competing interests
: Angela Damato: outside the submitted work, has received personal fees for the advisory role, speaker engagements, and travel and accommodation expenses from Ipsen, Servier, BMS, Merck Serono, Amgen, and Daiichi Sankyo. Francesca Bergamo: received personal honoraria as invited speaker from Eli-Lilly, MSD, Bristol Myers Squibb, AstraZeneca, Bayer, Pierre Fabre; participation in advisory board for AAA Novartis, Takeda, Teysuno. Filippo Pietrantonio: honoraria: Servier, Bayer, AstraZeneca, Lilly, MSD, Amgen, Pierre-Fabre, Merck-Serono, BMS, Astellas. Consulting or Advisory Role: Merck-Serono, Amgen, Servier, MSD, Organon, Bayer. Research Funding: Bristol Myers Squibb (Inst), AstraZeneca (Inst), Incyte, Agenus. Giuseppe Tonini: advisory board member of Molteni, MSD, Novartis, Roche, and Pharmamar. Elisa Giommoni: advisory board of Eli Lilly, Amgen, Viatris, BMS, Servier. Sara Leonardi: received honoraria (as invited speaker) from Roche, Eli Lilly, BMS, Servier, Merck Serono, Pierre Fabre, GSK, and Amgen; consulting fee (advisory boards) from Amgen, Astellas, Bayer, Merck Serono, Eli Lilly, AstraZeneca, Incyte, Daiichi-Sankyo, BMS, Servier, Merck Sharp & Dohme (MSD), GSK, Takeda, Rottapharm, and Beigene; as well as grants or funds (to institution) from Amgen, Merck Serono, Bayer, Roche, Eli Lilly, AstraZeneca, and BMS. Nicola Normanno: outside the submitted work personal fees for the advisory role, speaker engagements, and travel and accommodation expenses from AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Eli Lilly, Illumina, Incyte, MERCK, Merck Sharp & Dohme, Novartis, Roche, Servier, Thermofisher; financial support to research projects from Astrazeneca, Biocartis, Illumina, MERCK, QIAGEN, Roche, Sophia Genetics, Thermofisher. Carmine Pinto: outside the submitted work personal fees for the advisory role, speaker engagements, and travel and accommodation expenses from Amgen, Astellas, AstraZeneca, Bayer, Bristol Meyer Squibb, Celgene, Clovis Oncology, Eisai, Ipsen, Janssen, Incyte, Merck-Serono, Merck Sharp and Dohme, Novartis, Roche, Sandoz, Sanofi, and Servier. The other authors have no conflicts of interest to declare.
